A phase 3 trial of simufilam (NCT05575076) was started in November 2022 to assess the long-term safety and tolerability of simufilam in participants with mild-to-moderate AD
Pohunkov H, Stehlk J, Vchal J, Cech O, Adam M
Bremelanotide (PT-141) has several unique attributes that make it a noteworthy treatment option for sexual dysfunction: While PT-141 is an innovative treatment for sexual dysfunction, it also carries some risks and considerations that should be taken into account: Research into PT-141 has provided solid evidence for its efficacy and safety: Bremelanotide (PT-141) represents a significant advancement in the treatment of sexual dysfunction, providing an option that directly targets libido through a novel mechanism of action
Some are celebrating improved metabolic markers
This single-fluorophore tension indicator enables subtle tension changes to be visualized simply from color tone under superresolution microscopy
However, alcohol interferes with the absorption of B vitamins and depletes them from your system